



Canadian Liver Foundation
Fondation canadienne du foie

*Bringing liver research to life
Donner vie à la recherche sur le foie*



2020 Annual Report



Message from Jennifer Nebesky, President & CEO

2020 marked my first year as CEO at the Canadian Liver Foundation, and I learned a lot about this community and the importance of our work during this time. If I had to choose one word to capture what 2020 meant for us as an organization, it would be “change,” and in this case, change was an exciting and positive theme for the CLF.

The impact of the global COVID-19 pandemic was felt significantly throughout 2020. Without the ability to host in-person fundraising events like our Stroll for Liver, LIVERight Galas, LIVERight Health Forums and Living With Liver Disease sessions, we found ourselves needing to adapt and pivot fast so we could continue to deliver our services without interruption. Those living with and affected by liver disease still needed us, and we stepped up to the challenge.

We brought the majority of our work into the virtual space, which presented a unique opportunity – suddenly, we could deliver our education programs, patient support, awareness efforts and fundraising activities to people all across the country and beyond. We saw hundreds of Canadians join our national Stroll for Liver virtually, participating with their families in their local communities and setting a new record of funds raised for the event in our history. Our LIVERight Health Forums and Living With Liver Disease sessions were no longer limited by location, and we saw people joining from cities and towns throughout Canada, allowing us to reach even further into the liver disease community.

In keeping with the theme of change at the CLF, 2020 also marked the end of Dr. Morris Sherman’s tenure as Chair of the CLF Board of Directors. Dr. Sherman held this position from 2009 to 2020, and we welcomed Elliott Jacobson as our new Chair starting in January of 2021. We are so grateful for Dr. Sherman’s contributions as Chair, and it is thanks to leaders like him that we have been able to continuously provide support to our community and progress liver disease research and care. We’ve been pleased and excited to continue this work with Elliott Jacobson as we look ahead.

While the effects of COVID-19 were significant, I see a silver lining to the change we experienced in 2020. The pandemic pushed us as a team to aim higher and adapt, allowing us to show up for the liver community in Canada in more powerful ways than ever. And while change was the through-line in 2020, because of it we are positioned now to grow and evolve in exciting new ways to further establish our role as the leading voice for liver care in Canada.

Finally, my biggest learning was this: we are better when we stand together and rally around our shared vision of bringing research to life and improving the lives of every Canadian affected by liver disease. Together, we will continue to bring this spirit to everything we do and put you, our community, first.

Respectfully submitted,

Jennifer Nebesky
President & CEO
Canadian Liver Foundation

ABOUT THE CLF

In 1969, the Canadian Liver Foundation was born out of the passion and concern of a committed group of business leaders and doctors who believed that liver disease needed a champion. With the help of volunteers, patients and families, researchers, doctors, donors, and corporate supporters who share our vision of a world without liver disease, we are *bringing liver research to life*.

Throughout our history, we have been passionate about research, patient support, advocacy, and public information and awareness. We remain the only non-governmental organization in Canada focused on liver health and the main source of non-profit funding for all forms of liver research.

Our Mandate

The Canadian Liver Foundation's mandate is to promote liver health and reduce the incidence and impact of liver disease by providing support for research and education into the causes, diagnoses, prevention and treatment of liver disease.

Our Vision

A world without liver disease.

Our Mission

Bringing liver research to life for all Canadians. Research is the key to minimizing the impact on people affected by liver diseases, but it's only as good as its practical application. Through our advocacy, education and patient support efforts, we share the knowledge gained through research to improve the lives of liver disease patients and protect others who are at risk.

2019 – 2020 BOARD OF DIRECTORS

Morris Sherman MD, FRCPC
Chairperson

Kevork Peltekian MD, FRCPC
*Past Chairperson and Chairperson,
International Advisory Committee*

Elliott M. Jacobson FCPA, FCA, ICD.D
Secretary/Treasurer

Eric Yoshida MD, FRCPC
Chairperson, Medical Advisory Committee

Pascale Cloutier
Marketing and Communications Advisory Committee

Diana Mager PhD, MSc, RD
Chairperson, National Education Advisory Committee

Rick Jeysman
Chairperson, National Advocacy Advisory Committee

Michael Betel
*Marketing and Communications
Advisory Committee*

Kim Ewasechko
Finance Committee

Marco Galego
Finance Committee

Nelson Lee
Finance Committee

**Richard A. Schreiber MD, CM,
FRCPC, FAASLD**

Mel Krajden MD, FRCPC
Medical Advisory Committee

Marc Bilodeau MD, FRCPC

Jordan Feld MD, MPH

RESEARCH PROJECTS

The Canadian Liver Foundation is proud to support the work of Canadian researchers who share our mission of “bringing liver research to life.” In 2020, we awarded grants to support eight incredible research projects:

Operating Grants

Dr. Johane Allard
University of Toronto

Improving understanding of the links between intestinal bacteria and the immune system and the impact on Non-Alcoholic Fatty Liver Disease (NAFLD).

Non-alcoholic fatty liver disease (NAFLD) can progress to liver inflammation and scarring (fibrosis) leading to cirrhosis and transplantation. Intestinal bacteria may activate liver immune cells and increase NAFLD severity, but some intestinal bacteria may be protective. Dr. Allard's research objective is to improve understanding of how intestinal bacteria contributes to the progression of NAFLD, which may be helpful in exploring future treatments to minimize severity of this liver disease.



Dr. Mamatha Bhat
University Health Network

Guided delivery of medicine into the liver to treat liver cancer.

Patients with cirrhosis who develop liver cancer often cannot tolerate therapy due to inadequate liver function. Dr. Bhat's research objective is to evaluate whether a carrier that behaves like a lipoprotein (fat transporter) will limit side effects in patients with chronic liver disease who develop liver cancer. This study will demonstrate for the first time whether it is possible to safely use a natural fat transporter-like carrier to treat liver cancer even with cirrhosis.



Dr. Damien D'Amours
University of Ottawa

The Smc5/6 complex: A powerful and natural cure for hepatitis B virus infection.

Hepatitis B virus is a major cause for liver dysfunction and infects more than 350 million individuals worldwide. Our body encodes a natural cure that protects us from viral hepatitis: the Smc5/6 complex. Unfortunately, the hepatitis B virus has evolved a strategy to short-circuit this natural protection. Dr. D'Amour's research objective is to develop a new treatment pathway capable of re-activating the natural capacity of cells to defend themselves against hepatitis B infection. Achieving this will help to identify a potential cure for liver dysfunction in hepatitis B-infected individuals.



Graduate Studentships

Ms. Amber Hager

University of Alberta

Supervisor: Dr. Diana Mager

The effect of a 12-week home-based exercise program on muscle-mass, strength and quality of life in children with sarcopenia who have undergone liver transplantation.

Sarcopenia is a condition that is associated with low muscle mass, low muscle strength and impaired physical performance. Sarcopenia is very common in children and adults with liver disease before and after liver transplantation. Ms. Hager's research objective is to develop a home-based progressive exercise program using resistance bands to study whether this results in improvements in muscle mass, muscle strength and overall ability to participate in routine physical activity resulting in significant improvements in health-related quality of life.



Ms. Golasa Samadi Kochaksaraei

University of Calgary

Supervisor: Dr. Carla S. Coffin

Burden of chronic hepatitis B in women of childbearing age.

The most common transmission of the hepatitis B virus is when it is passed from mother to child during childbirth. Providing hepatitis B virus vaccine to the infant is ~90% effective in reducing the risk of transmission, however, failure can occur if the mother has a high level of the virus. Therefore, it is recommended that pregnant women with chronic hepatitis B receive treatment prior to giving birth. Ms. Kochaksaraei's research objective is to determine outcomes of hepatitis B treatment use in pregnancy in a large multiethnic group of patients and to ultimately inform public health policy to achieve the World Health Organization's goal of viral hepatitis elimination by 2030.



Ms. Alicia Vachon

University of Manitoba

Supervisor: Dr. Carla Osiowy

Development of a new hepatitis B virus diagnostic test to measure hepatitis B virus level.

With chronic Hepatitis B infection, there is a heightened risk for developing liver cirrhosis and hepatocellular carcinoma (liver cancer). Monitoring of hepatitis B virus levels in chronic patients following treatment requires a liver biopsy sample and is not standardized. Ms. Vachon's research objective is to develop a new diagnostic test using serum hepatitis B virus RNA (a new biomarker of hepatitis B virus), to detect the amount of the virus in patients in order to improve patient management of chronic hepatitis B.



Summer Studentships

Ms. Karianne Desmarais

Université de Montréal

Supervisor: Dr. Christopher Rose

The impact of pre-liver transplant hepatic encephalopathy on post-transplant clinical consequences.

Hepatic Encephalopathy (HE) is a major complication of chronic liver disease (cirrhosis). The liver is unable to metabolize toxins in the liver which can affect the brain. This can lead to memory, coordination, motor difficulties and mood challenges. As the condition worsens, symptoms can progress to confusion, lethargy, major disorientation, coma or permanent brain damage. Ms. Desmarais' research objective was to determine whether the presence (or severity) of pre-liver transplant HE can help predict post-transplant clinical outcomes.



Mr. Ajaypaul Sidhu

University of Alberta

Supervisor: Dr. Puneeta Tandon



Liver radiology therapies for hepatocellular carcinoma – a co-developed video-based educational intervention to improve patient knowledge, attitudes and preparedness.

Current treatments for hepatocellular carcinoma (HCC) are led by radiology and include radiofrequency ablation, ethanol ablation, transarterial chemoembolization, and transarterial radioembolization. Since patients with HCC do not have access to evidence-based, patient-oriented information about these procedures, their benefits, and their complications, Mr. Sidhu's study aimed to assess the value of a patient-oriented animated teaching video about HCC radiology procedures on patient knowledge, attitudes, and overall preparedness. Mr. Sidhu hopes his videos will improve overall patient knowledge of HCC treatments and provide an acceptable, standardized teaching modality to enhance practitioner-patient engagement that will benefit patients in Canada and elsewhere.

2020 CLF-CASL GOLD MEDAL AWARD

The CLF established a Gold Medal Award in 1983 to recognize doctors and scientists who have made a significant contribution to moving the field of liver research forward. Today, the award is given jointly with the Canadian Association for the Study of the Liver (CASL). The knowledge gained from the collective research of Gold Medal awardees has provided the CLF with the information we need to help improve the lives of Canadians living with or at risk for liver disease.

Dr. Thomas Michalak
Memorial University of Newfoundland



Thomas I. Michalak MD, PhD, a Professor of Molecular Virology and Medicine (Hepatology) at the Memorial University of Newfoundland (retired), is one of the world's foremost experts in the field of viral hepatitis and liver disease and has made pivotal contributions to liver research in Canada and internationally.

His ground-breaking discoveries have changed fundamental concepts about the nature of hepatitis B and C viral infections. In 1985 Dr. Michalak established a ground-breaking research laboratory and utilized a novel disease model to study hepatitis B virus infection which generated several important scientific findings.

Colleagues and former students who have worked with Dr. Michalak have noted the significance of his many research contributions, as well as the valuable role that his mentorship has played for the careers of many young investigators who began their research careers under his tutelage and are in many cases now continuing his legacy as independent researchers.

2020 CASL-CLF SASS-KORTSAK AWARD

Dr. Andrew Sass-Kortsak was a Professor of Pediatrics at the University of Toronto and the Head of the Research Institute. His pivotal research and his dedication to training the next generation of scientists has helped to change the lives of children impacted by liver disease.

Dr. Sass-Kortsak passed away in 1986. In 1990, the Canadian Liver Foundation, in partnership with the Canadian Association for the Study of the Liver (CASL), created the Sass-Kortsak Award to honour the late Dr. Sass-Kortsak who made tremendous contributions to the field of pediatric hepatology and did much to further the work of the Foundation. The CLF is proud to carry on his simple yet powerful guiding principle: focus on the patient.

Dr. Ronald Sokol
University of Colorado Denver / Children's Hospital Colorado



Dr. Sokol received his medical degree from the University of Chicago Pritzker School of Medicine and did residency training in pediatrics at the University of Colorado, followed by a fellowship in pediatric gastroenterology at the Cincinnati Children's Hospital Medical Centre.

Currently the Section Head for Gastroenterology, Hepatology and Nutrition, and Associate Medical Director of the Pediatric Liver Centre and Liver Transplantation Program at the Children's Hospital Colorado Anschutz Medical Campus – among other appointments – Dr. Sokol maintains an active clinical practice focusing on pediatric liver disease and liver transplantation in children.

RESEARCH PARTNERS


The Canadian Liver Foundation is proud to support and work with a robust network of researchers across the country who have made liver research a priority in their labs and clinics.



PATIENT SUPPORT

Established in 1969, the CLF was the first organization in the world dedicated to raising funds to support liver research, education and patient support services. In 2020, the CLF responded to thousands of patient support inquiries from across Canada in English, French, Mandarin, Cantonese and Serbian. Patients, caregivers, and family members turned to the CLF to receive guidance on living with liver disease, how to navigate the healthcare system, treatment, requests for peer support or just to have a person to talk to who can provide some comfort and reassurance.

2020 was an unprecedented year as the world was confronted with a new health concern, COVID-19. The CLF remained a beacon of hope and support for individuals impacted by liver disease who were now also concerned about COVID-19. Due to COVID-19:



- In-person patient support services and community outreach activities were cancelled to protect the health and safety of our liver community.

- The CLF developed new online programs and educational resources to help patients, caregivers and healthcare providers better understand COVID-19 and its impact on liver disease and to ensure that much-needed patient support services continued to be offered during this time of uncertainty.

“Being diagnosed with liver disease is a frightening experience and there are often far more questions than answers. It can be very comforting to talk to others who know what you’re going through and to get information and advice from a trusted source.” - Richard

*Treasurer's Report***FINANCIAL HIGHLIGHTS**

I am pleased to provide the financial highlights for the year ended December 31, 2020.

2020 was a year of unparalleled challenges for charities as a result of the impact on our activities from the COVID-19 pandemic related lockdowns across Canada. The Canadian Liver Foundation (CLF) was no exception from this impact.

We felt this mainly as the Foundation's donations and chapter revenue fell approximately 15% to \$5.8 million in 2020 from \$6.9 million for 2019. Most of this decrease in revenue was seen throughout our chapters and regions where all in-person events and activities were cancelled due to COVID-19. The revenue earned from those specific activities fell by approximately 67% (from approximately \$2.2 million to approximately \$850,000).



Notwithstanding this material impact, CLF was able (unlike many in our field) to survive this as other sources of revenue remained relatively stable thanks to our very loyal donor base and our very quick pivot to increased online fundraising and "virtual" events under the leadership of our new (in 2020) Chief Executive Officer, Jennifer Nebesky.

In addition, we were able to access subsidies from the federal government (the Canadian Emergency Wage Subsidy (CEWS),) in the amount of approximately \$330,000. We were also the beneficiaries of support from both government and corporate grants in support of charities during the pandemic situation.

Without these revenues and the approximately 6.2% return on our investment portfolio which contributed approximately \$150,000 to our general fund, operations at the CLF would have not ended the year in as stable financial situation as we did.

Research Trust Fund revenues were approximately \$1.9 million in 2020 and \$2.0 million in 2019. These funds have paid out \$1.3 million in research programs in 2020 and \$2.0 million in 2019. In 2020, we also paid out \$368,000 in research grant disbursements. These fund research projects directly related to non-alcoholic fatty liver disease, liver cancer, hepatitis B, liver transplantation, and hepatic encephalopathy.

In total, we have paid out over \$1.6 million in 2020 in research programs and research grants compared to approximately \$2.6 million in 2019. This reduction reflects the fact that many hospitals "paused" research activities as resources were required to be re-deployed in response to the overarching demands arising from the COVID-19 pandemic.

Our support for current research and education and our commitments for future research continues. At the end of 2020 we have committed over \$480,000 for future research commitments. As is our policy, we only commit for research from resources available at the time of the commitment. In recognition of the existing economic uncertainty and the continuing slowdown in research activities we did not issue a call for competitive submissions for new research projects to start in 2021.

We are in a strong financial position to reactivate our competition and other calls for proposals when the level of liver research and education starts to recover as we have approximately \$5.2 million in our Research Trust Funds available to fund appropriate (based on the various fund requirements) research and education in future years.

Expenditures on Programs in 2020 were approximately \$2.4 million compared to \$3.4 million in 2019. This 30% decrease over 2019 reflects the rigour with which we screen these expenditures and as those activities slowed down on a sector-wide basis in response to changes and pressures wrought by the pandemic.

We have maintained operating efficiency with expenses (including fundraising and administration costs) being approximately \$2.4 million (\$2.9 million for 2019). The reduction (approximately 16%) reflects our measured and thoughtful response to the pandemic-related situation we found ourselves in.

Our financial position remains sound. At the end of 2020 we had current assets of \$2.3 million (\$2.0 million for 2019). Our investments are over \$6.2 million in 2020 compared to \$5.2 million in 2019. Additionally, there is \$739,000 cash and cash equivalents in our investment accounts which reflects the requirements of our Investment Policy Statement to maintain sufficient cash balances to support research and education project commitments.

As noted above, our annual investment return for 2020 was approximately 6.2% which translated to an excess of \$550,000 in interest, dividends, realized capital gains and portfolio value increase. On this, in addition to the \$150,000 in support of operations referred to above, approximately \$400,000 was for the benefit of our Research Trust Funds and Medical Research Funds.

Our total fund balances have increased in 2020 by \$1.2 million (17%). The General Fund has increased by \$606,000 (31%). Research Trust Funds have increased by \$1.0 million (24%). The Medical Research Fund has decreased by \$373,000 (44%) reflecting our ability to continue fund previously approved research grants as we maintain our policy (mentioned above) of granting funding for research only to the extent that we have realized and retained earnings to do so. Therefore, we have the ability to make previously committed payments in 2020 irrespective of the pressures that the COVID-19 pandemic brought. Unfortunately, an effect of the pandemic is that many other charities were unable to do so in 2020.

On behalf of the Foundation's Finance Committee, I want to express our sincere appreciation for the efforts and ongoing dedication of our volunteers, donors, program partners, our Auditors (Grant Thornton, LLP) and our investment advisors (Baskin Wealth Management Services), our controller, Cheryl Ahong and all our dedicated and hardworking staff.


Respectfully submitted,



Elliott M Jacobson, MBA, FCPA, FCA, ICD.D
Treasurer



REVENUE OVERVIEW



Individual Donations	\$2,474,686
Partnerships	\$1,934,756
Interest and unrealized gain on investments	\$550,261
Other	\$448,377
Government	\$393,453
Corporate Gifts	\$342,779
Gaming	\$132,215
Foundations	\$63,383
Estates	\$27,539
Total 2020 Revenue	\$6,367,449

Stroll For Liver 2020 Funds Raised

Atlantic	\$3,351	Manitoba	\$6,135
BC	\$22,799	Montreal	\$1,786
Calgary	\$34,904	Northern Ontario	\$3,135
Chatham	\$3,960	Ottawa	\$25,355
Cornwall	\$56	Pembroke	\$1,000
Toronto	\$15,711		
Stroll For Liver 2020 Total		\$118,192	



EXPENSE OVERVIEW

Total 2020 Expenses \$5,134,379

Charitable Activities**	\$2,727,242
Fundraising	\$1,075,339
Administration	\$1,331,798

**Charitable Activities

Research	\$1,641,364
Education, Public Information & Community Support	\$1,085,878
	\$2,727,242



OPERATIONS SUMMARY For the year ended December 31, 2020

	GENERAL FUND		RESEARCH TRUST FUNDS		MEDICAL RESEARCH FUND		TOTAL	
	2020	2019	2020	2019	2020	2019	2020	2019
REVENUE								
Donations & Chapter Revenue	\$3,882,432	\$4,946,224	\$1,934,756	\$1,965,119			\$5,817,188	\$6,911,343
Interest & Other Income	\$165,690	\$240,239	\$342,793	\$407,453	\$41,778	\$72,866	\$550,261	\$720,558
Total	\$4,048,122	\$5,186,463	\$2,277,549	\$2,372,572	\$41,778	\$72,866	\$6,367,449	\$7,631,901
EXPENDITURE								
Programs	\$1,084,049	\$1,372,207	\$1,273,578	\$1,981,557	\$1,829	\$1,931	\$2,359,456	\$3,355,695
Operating	\$2,407,137	\$2,948,807					\$2,407,137	\$2,948,807
Total	\$3,491,186	\$4,321,014	\$1,273,578	\$1,981,557	\$1,829	\$1,931	\$4,766,593	\$6,304,502
Excess Revenue Over Expenditure for General Fund	\$556,936	\$865,449					\$556,936	\$865,449
Excess Revenue Over Expenditure for Research Trust Funds			\$1,003,971	\$391,015			\$1,003,971	\$391,015
Excess Revenue Over Expenditure for Medical Research Fund					\$39,949	\$70,935	\$39,949	\$70,935
Research Grant Disbursements					(\$367,786)	(\$620,667)	(\$367,786)	(\$620,667)
Inter-Fund Transfers to Support Activities of the Medical Research Fund	\$48,744	(\$331,275)	(\$3,331)	(\$115,493)	(\$45,413)	\$446,768	\$0	\$0
Fund Balance - Beginning of Year	\$1,980,228	\$1,446,054	\$4,225,030	\$3,949,508	\$853,500	\$956,464	\$7,058,758	\$6,352,026
Fund Balance - End of Year	\$2,585,908	\$1,980,228	\$5,225,670	\$4,225,030	\$480,250	\$853,500	\$8,291,828	\$7,058,758

FINANCIAL POSITION For the year ended December 31, 2020

	GENERAL FUND		RESEARCH TRUST FUNDS		MEDICAL RESEARCH FUND		TOTAL	
	2020	2019	2020	2019	2020	2019	2020	2019
ASSETS								
Current	\$1,027,864	\$821,775	\$1,256,894	\$1,084,328	\$56,000	\$77,265	\$2,340,758	\$1,983,368
Investments	\$1,862,212	\$1,294,060	\$3,968,776	\$3,140,702	\$424,250	\$776,235	\$6,255,238	\$5,210,997
Capital Assets	\$22,356	\$48,140					\$22,356	\$48,140
Total	\$2,912,432	\$2,163,975	\$5,225,670	\$4,225,030	\$480,250	\$853,500	\$8,618,352	\$7,242,505
LIABILITIES	\$326,524	\$183,747					\$326,524	\$183,747
FUND BALANCE	\$2,585,908	\$1,980,228	\$5,225,670	\$4,225,030	\$480,250	\$853,500	\$8,291,828	\$7,058,758
Total	\$2,912,432	\$2,163,975	\$5,225,670	\$4,225,030	\$480,250	\$853,500	\$8,618,352	\$7,242,505

Complete financial statements, including explanatory notes, as audited by Grant Thornton LLP, are available from the Canadian Liver Foundation National office.

THANK YOU TO OUR DONORS

The generosity of our donors has allowed us to maintain lifesaving liver research, public education, and patient support efforts established over our 51-year history. We are deeply grateful for the support of the following organizations and individuals as their donations in 2020 allowed us to continue our mission of *"bringing liver research to life."*

\$25,000+

Kevin Wing Hon Ma	Intercept Pharmaceuticals
Ellen Pan	Merck Canada Inc
Aaron Pan	Novo Nordisk Canada Inc
AbbVie Corporation	Paladin Labs
Astellas Pharma Canada	Pfizer Canada ULC
AstraZeneca Canada Inc	Sexton Investments Ltd
Bristol-Myers Squibb Canada Co	SpecialtyRx Solutions
Gilead Sciences Canada	TD Canada Trust
Health Partners	Vancouver Bullion and Currency Exchange Ltd
Hoffmann-La Roche Limited	Walmart Canada Corp

\$10,000 - \$24,999

Kathryn Kennedy	Canadian OnLine Giving Foundation
Genevieve Lockhead	Eisai Limited Canada
Alexion Pharmaceuticals	Ellen Bialystok
Alnylam Pharmaceuticals Inc	Novartis Pharmaceuticals Canada Inc
Altimmune Inc	Apogee IT Services Canada
American Collegiate Educational Services	Shaw Charity Classic
Calgary Foundation	The Ottawa Hospital
Calgary Shaw Charity Classic Foundation	Theratechnologies Inc
	United Way of Chatham-Kent

\$5,000 - \$9,999

Calgary Chinatown Seniors' Centre Foundation	Shane Homes
City of Markham	Shaw Birdies for Kids
Edmonton Community Foundation	Tourisme Montreal / evenements D'affaire's Montreal
Florence MacKenzie Fund at Edmonton Community Foundation	United Way Central Alberta
KNS Canada Inc	United Way of Calgary & Area
Lohn Foundation	United Way of Toronto
London Drugs Ltd	

\$2,500 - \$4,999

Tom Burns	ATCO Gas
D James Christie	Canada ICI Capital Corporation
Dr Stephen Congly	Community Foundations of Canada
Nancy Eaton-Doke	Deloitte LLP
Dr Francis Ho	EFW Radiology
Elliott Jacobson	Jewish Foundation of Manitoba
Lynn Palangio	Lupin Pharma Canada
Dr Morris Sherman	Mable Chadwick Foundation

\$1,000 - \$2,499

Aili Aljas	Ming Shuen Leung	Agnes Yau
Janet & Gordon Baker	Joe Manget	Dr Eric Yoshida
Frank Baldock	William Marchant	Abbotsford Community Foundation
William Barnett	Mary Maselli	Air Canada - DCS team
Sean Basarke	Nathalie Massie	Albert Abram Lager Foundation
Janice Bateson	Rick McGraw	All Charities Campaign
J Richard Bird	Shannon McMullan	Almag Aluminun
Cynthia Blumenthal	Joyce McMurray	APC Alarm Corp
Ron Borys	Robert Michaleski	Atco Gas EPIC
Pat Bourque	Lisa Miller	BMO Nesbitt Burns
Murray Brasseur	Joan Moore	Butler Family Foundation
Trevor Bruno	Doug Morris	CAF Canada
Barbara Bruser	Ghazy Mujahid	Competition Oil Tools
Julie Burgess	Chieu Ngo	Cossette Communication Inc
Lars Callieou	Sandra Nymark	CTC Communication Corporation
Bruce Cappel	Donald Park	Digipom Inc
Monica Chan	Lowen Pawliw	EECOL Electric Corp
Elsie Choban	Nadine Pedersen	Government of Manitoba, Employees All Charites Campaign
Dr Carla Coffin	Greg & Linda Powell	Hiram Walker
Ronald Couvrette	Veronica Prokop	Kin Club of Windsor
Kathleen Curtis	Ariel Qute	La fondation Pierrot LeBrun
Donald Daly	Ravinmon Raveendrampillai	Lac du Bonnet & District Charitable Foundation Inc
Philip del Buey	Robert Rennie	Lenergy Resources Inc
Dr Marc Deschênes	Barbara Ritchie	LinkNow Media
Mohamed Elkaliouby	Linda Robinson	Norton Rose Fulbright
Antonieta Farley	Curt Sarbacher	Quintex Services Ltd
Angela Fok	Wu Shan	Scarborough H O G Chapter 9245

Cynthia Garbe	Randall Smith	Service OR/LP SEC
Lilli Gillman	Carole Taylor	The Ho's Benevolence Association of BC
Victor Girouard	Ivan Trush	The Nusbaum Family Foundation
George Gorzynski	Sid Vanderzwaag	The Vancouver Chinatown Lions Club Medical and Scholarship Foundation
Ann Graff	Mitch Walker	UBC-CLF
David Hunter	Shannon Wilson	Université de Montréal
Carol Jaffray	Don Wishart	University Health Network
Stephanie Johnston	Ralph Woessner	Wawanesa Mutual Insurance
Audrey Kenny	Allen Wong	Wellington Laboratories Inc
Hanson Lau	Sunny Wong	

\$500 - \$999

Stephen & Vicki Adams	Michael R Kent	Bruce Staal
Charles Allard	Brian Kjenner	Josephine Steinbach
John Amonson	Ramona Kuiack	Hee Sum Yip
Dennis & Lolita Augustine	Andrew Lai	Marie Laure Swiderski
David Bailey	Mary Laidlaw	Ta-Cheng Tai
Michael Baker	Yash Lamba	Kam Cheung Tam
Cornelis Balk	John Laratta	Bev Tamboline
Scott Bartlett	Bruno Laroche	Lucie Thirnbeck
Paul Beeston	Rive Le Lacheur	Michael & Renae Tims
Robert Bietz	Bonnie Leach	Dennis Tokaryk
Margaret Binek	Patrick Leblond	Frances Tong
Debbie & Roger Bloom	Stewart Leighton	Moses Paul Tooktoo
Danielle Blouin	Ruth Leistner	Ruth Torrey-Brockie
Paul Blythe	Greg Lenehan	Christie Traff
Barbara Bohne	Chungsen Leung	Arin Tsai
Emilien Bolduc	Jane Levac	Ricky Tsang
Melanie S Boscariol	Dr Gary & Karen Levy	B Vaz
Melanie Braga	Annie Li	Jocelyne Villeneuve
Ruth Brayer	Bensan Li	Janice Voyer
Raymond Breton	William Lightfoot	Louis Wadsworth
Terry Brookes	Edward Lillicrop	Richard Walker
Christine Brown	David & Donna Lincoln	Jane Walker
James Brown	Kexing Liu	Sheila Walsh
Rae Brown	Gar Liu	Larry & Leanne Walton
Dr Kelly Burak	Peter Lo	Mary Watson
Denis Cadieux	Sharon Loyek	Penny Watson
Ann Calvert	Tim Lung	Cal Wenzel

Paul F Campbell	Karen Lyon	Judith White
Susan Campbell	Kenneth MacLean	D Lee Whittington
Alice Cao	Gisela MacPhail	Cynthia Willemson
David Carey	William Maedal	Shannon Wilson
Derek Caron	Edmund Maidlow	Richard Wolfe
Pascale Cloutier	Linda Mann	Susan Wong
Walter Conrad	Wayne Manuliak	Xiang Xiao
F Tom Cowan	Norah Marr	Ran Xu
Owen Curtis	Nicholas Martens	Wesley Yeo
Raymond Daepp	Doreen Martindale	Angela Yeung
Linda Dalziel	Teri Matula	Hee Sum Yip
Mark Darroch	K McArthur	Man Fong Yip
Meghann Darroch	Sarah McAuley	Vicki Zaharko
Heidi Deans	Ken McCance	Anastazja Zvoleff
Giovanni Delfino	Dan McDugall	I I 2008 I BC Ltd
Ludka Dencev	Isabell McDorman	Abbarch Architecture Inc
Tyler Derond	Dan McDougall	Absopulse Electronics Ltd
Vernon Desrosiers	Roger McGillvray	Alberta Utilities Commission
Bruce Devenney	Joan McLeod	Albert's Generator Services Inc
Marilyn Dickinson	Dr Thomas Michalak	Atlantic Hepatology
Dino C Drigo	Darlene Mothe	Boissevain/Morton Donor's Choice
Steve & Kathy Duke	Joseph Mrkonjic	Bozzinis Restaurant
Mary Joan Dunn	John Mueller	Broadwaylive Music Productions Ltd
Penny Dyte	Donny & Linda Mulrain	Caisse de Bienfaisance des employés et retraités du CN
Christopher Easthope	Ed Muscat	Canada Gives
Carol Ann Elliott	Joseph Natywary	Canada Life
Rodney Ellis	Valerie Neill	Confidence Management Ltd
Savvas Farassoglou	Thomas Nelson	Coquitlam College
R Farewell	Linda Newman	Cornell's Repair Center
Robert J Fenn	Susanna Ng	Corporation of the City of London
Pamela Fish	Ernest Ng	Crown Distributors
John Fisher	Armagail North	Dawn and Axel Foundation
Sylvia Fossum	Elizabeth G O'Brien	Dorbar Insurance Agency Inc
Robin Fry	Klas Ohman	Epicure Fundraiser Group!
Joanne Furino	Lesley Oligmueller	Eric & Elma Sommerfeld Charitable Gift Fund
Marc-André Gagné	Dan Pasqua	FWS Group of Companies
J Robert Gaynor	Rob & Ruth Peters	George & Karen Erb Foundation
Edward Ghent	Bruce Pettersen	Hillis & Jo Ann Thompson Family Foundation

Brian Goeres	Brook Pimm	J S Cheng & Partners Inc
Janet R Gouinlock	Ron Poelzer	Johnston Drug Wholesale Ltd
Norma Gregson	Sheri Porter	Lac du Bonnet Ice Fishing Derby
Yvette Grossi	Lynda Powell	Lola Stroud Charitable Fund
Quan Gu	Valerie Prokop	Ludwar Law Firm
Horst Hagen	Barry Quon	Manitoulin Transport
Sandy Hall	Elizabeth Rempel	Metro Marine Corp
Don Hanson	Lorelei Reynolds	Murray's Trucking Inc
Irene Hapanowicz	James Ridgway	Nesbitt Burns
Dorene Harding-Ilskens	Grace A Roberts	NHL Officials Association
Robert Harper	Della Roberts	Orchardview Pharmacy Ltd
Rochelle Harries	Trevor Robertson	Peel Scrap Metal Recycling Ltd
Tim Harvie	George J Rogers	Pepsico
David & Lenore Hawkey	Albert Rutledge	Prop Works Propeller Systems Inc
Dr Jenny Heathcote	John Sanford	Provincial Employees Community Service Fund
Joanne Hetherington	Anne Sawa	Rayjo Charitable Trust
Katie P Y Ho	Naveeda Sayyed	The City of Winnipeg Employees' - Retirees' Charitable Giving
Julienne Huys	Robert Shewchuk	The Dawn & Axel Rehkatsch Foundation
Peter Jansen	Maureen Short	Theratechnologies
Mark Jeffrey	Dr Naglaa Shoukry	United Way of Cape Breton
Alexandra Jenkins	Clayton & Roxanne Sissons	United Way of Manitoba
Signe Jurcic	Douglas Smiley	Victoria Deck Ltd
A Karpluk	Ron Smit	VIP Events Inc
Doug Kavanagh	J Russ Smith	
R Kenny	Nancy Smith	

Third Party Donors

Virtual Bingo	Little Heroes
Dior Fundraiser	Little Heroes Talent Show
Lac du Bonnet Ice Fishing Derby	VIP Events Inc

Bequests

Estate of Larry Brownlee	Estate of John Douglas Kent Sanderson
Estate of Reita Eileen Moyn	Estate of Ellen (Ella) Strain

**Canadian Liver Foundation
National Office:**

3100 Steeles Ave, suite 101
Markham, Ontario L3R 8T3

www.liver.ca
(416) 491-3353
1-800-563-5483

info@liver.ca



Canadian Liver Foundation
Fondation canadienne du foie

*Bringing liver research to life
Donner vie à la recherche sur le foie*